RP 56142 | 78088-46-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: RP 56142
• 英文别名: Tabilautide；(2S,6S)-6,7-diamino-2-[[(4R)-4-carboxy-4-[[(2S)-2-(dodecanoylamino)propanoyl]amino]butanoyl]amino]-7-oxoheptanoic acid
• CAS: 78088-46-7
• 化学式: C₂₇H₄₉N₅O₈
• 分子量: 571.715
• InChiKey: TUNXCNXMSJZNPO-XSDIEEQYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  40
• 可旋转键数：
  24
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  231
• 氢给体数：
  7
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  (2S,6S)-7-amino-2-[[(4R)-4-[[(2S)-2-(dodecanoylamino)propanoyl]amino]-5-oxo-5-phenylmethoxypentanoyl]amino]-7-oxo-6-(phenylmethoxycarbonylamino)heptanoic acid 生成 RP 56142
  参考文献：
  名称：

  BOUCHAUDON, JEAN;DUTRUC-ROSSET, GILLES;FARGE, DANIEL;JAMES, CLAUDE, J. CHEM. SOC. PERKIN TRANS. PT 1,(1989) N, C. 695-701

  摘要：

  DOI：

文献信息

• [EN] THIOSEMICARBAZATES AND USES THEREOF<br/>[FR] THIOSEMICARBAZATES ET LEURS UTILISATIONS
  申请人：FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH

  公开号：WO2020227592A1

  公开（公告）日：2020-11-12

  Thioesters, thiocarbamates, thiocarbazates, semithiocarbazates, peptides, aza-amino acid conjugates, and azapeptides; and a chemoselective and site-specific functionalization protocol of protected thiocarbazates and semithiocarbazates are described. The protocol features the use of Mitsunobu reaction to alkylate specifically the nitrogen atom close to the acylthiol moiety with alcohols to produce protected mono-substituted thiocarbazates that can be stored for months, activated under mild conditions at low temperature using halonium reagents and integrated orthogonally to make substituted semicarbazides that can be used, e.g., as synthons in synthesis of aza-amino acid conjugates, azapeptides and other peptidomimetics. Methods for preparing and using ureases, carbazides, semicarbazides, beta-peptides, azapeptides, and other peptidomimetics and azapeptide conjugates, and uses of ureases, carbazides, semicarbazides, beta-peptides, azapeptides in drug discovery, diagnosis, inhibition, prevention and treatment of diseases are also described.

  巯酯，硫代氨基甲酸酯，硫代氨基甲酸酯，半硫代氨基甲酸酯，肽，氮代氨基酸共轭物和氮代肽；以及一种对受保护的硫代氨基甲酸酯和半硫代氨基甲酸酯进行化学选择性和位点特异性功能化的方法被描述。该方法采用三甲基脲反应特异性烷基化靠近酰硫醇基团的氮原子，使用醇生成可储存数月的受保护的单取代硫代氨基甲酸酯，在低温下使用卤化物试剂轻微条件下激活，并与其他基团正交集成以制备取代半氨基甲酸酰胺，例如，可用作氮代氨基酸共轭物，氮代肽和其他肽类模拟物的合成中间体。还描述了制备和使用尿酶，卡巴酰胺，半氨基甲酸酰胺，β-肽，氮代肽和其他肽类模拟物以及氮代肽共轭物的方法，以及尿酶，卡巴酰胺，半氨基甲酸酰胺，β-肽，氮代肽在药物发现，诊断，抑制，预防和治疗疾病中的用途。
• [EN] METHODS OF SYNTHESIZING N-HYDROXYSUCCINIMIDYL CARBONATES<br/>[FR] PROCÉDÉS DE SYNTHÈSE DE CARBONATES DE N-HYDROXYSUCCINIMIDYLE
  申请人：XENOPORT INC

  公开号：WO2010017498A1

  公开（公告）日：2010-02-11

  The present disclosure relates to methods of synthesizing N-hydroxysuccinimidyl-carbonate intermediates from the corresponding sulfones useful in the preparation of 1-(acyloxy)-alkyl carbamate prodrugs.

  本公开涉及一种从相应砜合成N-羟基琥珀酰亚胺-碳酸酯中间体的方法，该中间体在制备1-(酰氧基)-烷基氨甲酸酯前药中有用。
• METHOD OF MAKING 1-(ACYLOXY)-ALKYL CARBAMATE COMPOUNDS
  申请人：XENOPORT, INC.

  公开号：US20140243544A1

  公开（公告）日：2014-08-28

  Methods of preparing carbamate prodrugs of amine-containing drugs are provided. Carbonates useful in the synthesis of the carbamate prodrugs are also provided.

  提供了制备胺类药物的氨基甲酸酯前药的方法。还提供了在合成氨基甲酸酯前药中有用的碳酸盐。
• [EN] PEPTIDOMIMETIC AGENTS, SYNTHESIS AND USES THEREOF<br/>[FR] AGENTS PEPTIDOMIMÉTIQUES, SYNTHÈSE ET UTILISATIONS DE CEUX-CI
  申请人：FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH

  公开号：WO2020227588A1

  公开（公告）日：2020-11-12

  Compounds for use in synthesis of peptidomimetic agents; synthesis of peptidomimetic agents; peptidomimetic diagnostic and therapeutic agents; and uses of the compounds and peptidomimetic agents in drug discovery, diagnosis, prevention and treatment of diseases are described.

  描述了用于合成肽类模拟药物的化合物；合成肽类模拟药物；肽类模拟诊断和治疗剂；以及化合物和肽类模拟药物在药物发现、诊断、预防和治疗疾病中的用途。
• Use of n-substituted-1,5-dideoxy-1,5-imino-d-glucitol compounds for treating hepatitis virus infections
  申请人：Mueller A. Richard

  公开号：US20050119310A1

  公开（公告）日：2005-06-02

  Provided are methods and compositions for treating hepatitis virus infections in mammals, especially humans. The methods comprise (1) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds alone or in combination with nucleoside antiviral agents, nucleotide antiviral agents, mixtures thereof, or immunomodulating/immunostimulating agents, or (2) administering N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compounds alone or in combination with nucleoside antiviral agents, nucleotide antiviral agents, or mixtures thereof, and immunomodulating/immuno-stimulating agents.

  提供了一种治疗哺乳动物，尤其是人类肝炎病毒感染的方法和组合物。该方法包括（1）单独或与核苷类抗病毒药物、核苷酸类抗病毒药物、二者的混合物或免疫调节/免疫刺激剂结合使用N-取代-1,5-二脱氧-1,5-亚氨基-D-葡萄糖醇化合物，或（2）单独或与核苷类抗病毒药物、核苷酸类抗病毒药物、或二者的混合物以及免疫调节/免疫刺激剂结合使用N-取代-1,5-二脱氧-1,5-亚氨基-D-葡萄糖醇化合物。